105 related articles for article (PubMed ID: 28880970)
1. Optimization of Western blotting analysis for the isolation and detection of membrane xenobiotic transporter ABCG2.
Szczygieł M; Markiewicz M; Szafraniec M; Zuziak R; Urbańska K; Fiedor L
Acta Biochim Pol; 2017; 64(3):437-443. PubMed ID: 28880970
[TBL] [Abstract][Full Text] [Related]
2. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
3. Transcription factor-mediated regulation of the BCRP/
Gorczyca L; Aleksunes LM
Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):239-253. PubMed ID: 32077332
[No Abstract] [Full Text] [Related]
4. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.
Storch CH; Ehehalt R; Haefeli WE; Weiss J
J Pharmacol Exp Ther; 2007 Oct; 323(1):257-64. PubMed ID: 17652262
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.
Leslie EM; Deeley RG; Cole SP
Toxicol Appl Pharmacol; 2005 May; 204(3):216-37. PubMed ID: 15845415
[TBL] [Abstract][Full Text] [Related]
6. Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
Szafraniec MJ; Szczygieł M; Urbanska K; Fiedor L
Drug Metab Rev; 2014 Nov; 46(4):459-74. PubMed ID: 25036722
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
8. Expression and Activity of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Distal Lung Epithelial Cells In Vitro.
Nickel S; Selo MA; Fallack J; Clerkin CG; Huwer H; Schneider-Daum N; Lehr CM; Ehrhardt C
Pharm Res; 2017 Dec; 34(12):2477-2487. PubMed ID: 28470471
[TBL] [Abstract][Full Text] [Related]
9. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
10. Optimization of sample preparation for transporter protein quantification in tissues by LC-MS/MS.
Jankovskaja S; Kamiie J; Rezeli M; Gustavsson L; Sugihara Y; Miliotis T; Ruzgas T; Marko-Varga G
J Pharm Biomed Anal; 2019 Feb; 164():9-15. PubMed ID: 30339949
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
12. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters.
Choudhuri S; Klaassen CD
Int J Toxicol; 2006; 25(4):231-59. PubMed ID: 16815813
[TBL] [Abstract][Full Text] [Related]
13. Impact of breast cancer resistance protein on cancer treatment outcomes.
Ross DD; Nakanishi T
Methods Mol Biol; 2010; 596():251-90. PubMed ID: 19949928
[TBL] [Abstract][Full Text] [Related]
14. Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein.
Lou Y; Guo Z; Zhu Y; Zhang G; Wang Y; Qi X; Lu L; Liu Z; Wu J
J Ethnopharmacol; 2019 Jan; 228():82-91. PubMed ID: 30243825
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
16. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
17. Effect of capsaicin on breast cancer resistance protein (BCRP/Abcg2) and pharmacokinetics of probe substrates in rats.
Chen F; Wang L; Zhai X; Wang N; Qin Y; Zhu C; Wu S; Lu Y
Xenobiotica; 2022 Feb; 52(2):209-217. PubMed ID: 35345975
[TBL] [Abstract][Full Text] [Related]
18. Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport.
Cai X; Bikadi Z; Ni Z; Lee EW; Wang H; Rosenberg MF; Mao Q
J Pharmacol Exp Ther; 2010 Jun; 333(3):670-81. PubMed ID: 20203106
[TBL] [Abstract][Full Text] [Related]
19. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
20. Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective.
Goncalves J; Bicker J; Alves G; Fortuna A; Falcao A
Curr Drug Metab; 2018; 19(12):1021-1041. PubMed ID: 29956624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
